Entries by Wally Graham

Patrys completes successful clinical trial

THE PHARMACY: Patrys Limited (ASX: PAB) has received final results from a Phase I/IIa, open-label study of PAT-SM6 in patients with refractory or relapsed multiple myeloma (MM). Patrys explained the trial was conducted in 12 patients (10 male and 2 female, median age 71 years) with refractory or relapsed MM. The primary endpoint of the […]

Regeneus osteoarthritis treatment shows continued improvement

THE PHARMACY: Regenerative medicine company, Regeneus (ASX: RGS) announced further results from its ethics approved joint registry used to track the safety and effectiveness of the company’s innovative cell therapy, HiQCell®, in the treatment of osteoarthritis. The interim report of 305 patients, as at 23 January 2014, has found that: Patients reported continued improvements at […]

Hi Ho, Hi Ho, it’s off to work we go

THE DRILL SERGEANT: Each week any number of junior exploration plays set out to drill their ground. Here’s a small selection of what’s been happening this week. Commencement of Mining Mineral Deposits (ASX: MDL) has commenced mining at Grande Côte in Senegal, with sand now being processed through the Wet Concentrator Plant (WCP), producing heavy […]

Arunta Resources produces tungsten concentrate

THE DRILL SERGEANT: Arunta Resources (ASX: AJR) has received results from metallurgical test work recently carried out at the company’s 100 per cent-owned Hatches Creek tungsten project, located north-east of Alice Springs in the Northern Territory. According to Arunta the results have shown the project possesses the ability to produce saleable tungsten concentrates from existing […]

Blackthorn Resources progressing Kitumba study update

THE DRILL SERGEANT: Blackthorn Resources (ASX: BTR) has released an update on the progress of a Pre-feasibility Study Optimisation program being carried out at the company’s Kitumba copper project in Zambia. Blackthorn Resources commenced the Study Optimisation program following the completion of a preliminary Prefeasibility Study (PFS) in September 2013 of the Kitumba project.   […]

Mithril Resources defines new EM conductors at Kambalda

THE DRILL SERGEANT: Mithril Resources (ASX: MTH) has identified new anomalies during electromagnetic (EM) geophysical surveying at the Hendrix and Floyd nickel prospects at the company’s West Kambalda project in Western Australia. Mithril has recently completed a program of geological mapping, and Moving Loop EM (MLEM) geophysical surveying with the aim of identifying geophysical anomalies […]

Impact Minerals extends Commonwealth exploration potential

THE DRILL SERGEANT: Impact Minerals (ASX: IPT) has taken receipt of high-grade rock chip samples with assays of up to 18.2 per cent copper and 58 grams per tonne silver from the company’s 100 per cent-owned Commonwealth project in New South Wales. Impact claims the results have extended the strike length of the known mineralised […]

Carpentaria releases Hawsons maiden Resource

THE DRILL SERGEANT: Carpentaria Exploration (ASX: CAP) has released a maiden Indicated Resource and a 20 per cent increase in contained premium quality magnetite concentrate for the company’s Hawsons iron project located near Broken Hill, New South Wales. The Hawsons project is a Joint Venture between Carpentaria Exploration (60 per cent) and private resources investor […]

Patrys advances PAT-LM1 to clinical development

THE PHARMACY: Clinical stage biotechnology company Patrys Limited (ASX: PAB) has released an update on the development program for the company’s anti-cancer product, PAT-LM1. Patrys said PAT-LM1 is the second IgM antibody in the company’s pipeline to enter clinical development. The company explained PAT-LM1 is a natural human antibody that has shown much promise in […]

Imugene allowed Israel patent for cancer vaccine

THE PHARMACY: Australian biopharmaceutical company Imugene Limited (ASX: IMU) has been issued an Intention to Grant notice from the Israeli Patent Office for the company’s proprietary cancer vaccine HER-Vaxx (Patent no. IL 194162, 2027expiry). In its announcement to the ASX Imugene explained HER-Vaxx to be a proprietary therapeutic cancer vaccine that stimulates a polyclonal antibody […]